Behçet’s syndrome (BS) is a variable vessel vasculitis that mainly involves the skin and mucosa, eyes, musculoskeletal system, blood vessels, gastrointestinal, and nervous systems. Musculoskeletal involvement occurs in around one-half of the patients during their disease course. Arthritis, arthralgia, and enthesitis are the typical musculoskeletal manifestations of BS. Recurrent attacks of nonerosive monoarthritis is the most common form of arthritis. Knees and ankles are the most frequently involved joints, followed by wrists, elbows, and hands. The majority of arthritis episodes resolve within weeks. Less commonly, longer episodes can occur and some patients may have polyarticular involvement affecting the fingers. Colchicine is usually the first-line agent for the management of arthritis and short-term low-dose glucocorticoids may be used during acute attacks. Azathioprine is also an effective option. Despite the lack of controlled studies, sulfasalazine and methotrexate may be tried in selected cases. TNF inhibitors can be used in refractory patients.

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Musculoskeletal Manifestations in Behçet’s Syndrome

  • Mert Öztaş,
  • Gülen Hatemi

摘要

Behçet’s syndrome (BS) is a variable vessel vasculitis that mainly involves the skin and mucosa, eyes, musculoskeletal system, blood vessels, gastrointestinal, and nervous systems. Musculoskeletal involvement occurs in around one-half of the patients during their disease course. Arthritis, arthralgia, and enthesitis are the typical musculoskeletal manifestations of BS. Recurrent attacks of nonerosive monoarthritis is the most common form of arthritis. Knees and ankles are the most frequently involved joints, followed by wrists, elbows, and hands. The majority of arthritis episodes resolve within weeks. Less commonly, longer episodes can occur and some patients may have polyarticular involvement affecting the fingers. Colchicine is usually the first-line agent for the management of arthritis and short-term low-dose glucocorticoids may be used during acute attacks. Azathioprine is also an effective option. Despite the lack of controlled studies, sulfasalazine and methotrexate may be tried in selected cases. TNF inhibitors can be used in refractory patients.